Search For

Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall?

KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer

Cisplatin resistance in head and neck squamous cell carcinoma is linked to DNA damage response and cell cycle arrest transcriptomics rather than poor drug uptake

Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors

Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines

Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies

Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance

Resistance signatures manifested in early drug response across cancer types and species

New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer

ROS1 mutations promote an immunosuppressive tumor microenvironment via MYC to confer immune evasion in head and neck cancer

Lactylation: a novel driver of drug resistance in the tumor microenvironment

Super-enhancer inhibitors THZ2 and JQ1 reverse temozolomide resistance in glioblastoma by suppressing SE-driven SOX9 expression